Lynparza (Olaparib), First Treatment Approved for Breast Cancer Caused by Specific Gene Mutation

FRIDAY, Jan. 12, 2018 -- Lynparza (olaparib) has been approved by the U.S. Food and Drug Administration to treat spreading breast cancer caused by a BRCA gene mutation. The drug is among a class called poly ADP-ribose polymerase (PARP) inhibitors,...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news